Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vero cell-derived trivalent influenza vaccine in adults 50+ years
NCT00782431Phase 3Completed
- Sponsor
- Resilience Government Services
- Start
- Nov 2008
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Butantan Influenza Trivalent, Fragmented and Inactivated in influenza (2 arms), sponsored by Resilience Government Services. Primary endpoints: Percentage of Subjects With Seroconversion Antibody Titer at 21 days and Percentage of Subjects With Seroprotective Antibody Titer at 21 days. Started Nov 2008; status: completed.
02
Drugs
Butantan Influenza Trivalent, Fragmented and Inactivated
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00782431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782431.